Replimune TUDRIQEV commercially available for advanced melanoma
Replimune reported strong initial engagement from healthcare providers for TUDRIQEV's launch and affirmed its fiscal 2027 financial outlook, following FDA clearance for the oncolytic immunotherapy.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed